Genting Singapore's 3Q18/9M18 adjusted EBITDA of S$318.8m/S$943.6m was in line at 78%/76% of our/consensus (S$1.21bn/S$1.24bn) FY18F.
At 5.9x forward EV/EBITDA, the market is likening GENS’s prospects to the “down years” of FY15- 16, but we do not believe it is that dire.
We trim our FY19- 20F estimates and Target Price to S$1.28 (now based on 10x FY19F EV/EBITDA (vs. 11.5x), its 5- year historical mean). Retain ADD.
Adj. EBITDA Up on Sustained GGR Growth and Better Non-gaming
Genting Singapore's 9M18 adj. EBITDA rose 5.3% y-o-y to S$943.6m (vs. 9M17: S$895.9m) as 9M18 gaming revenues (+2.3% y-o-y) were augmented by a 6.6% y-o-y jump in 9M18 non-gaming revenue.
Low trade receivables impairment (9M18: S$22.5m vs. 9M17: S$43.6m) also contributed to the improvement in 9M18 adj. EBITDA margin (50.3% vs. 9M17: 49.4%).
9-Month core EPS was 83.7% of our full-year forecast.
VIP Up on Higher Market Share; Mass Holding Steady
Estimated 3Q18/9M18 VIP GGR grew 5.7%/20.6% y-o-y on higher VIP market share of 46.8%/48.5% (vs. 3Q17/9M17: 37%/35.6%), despite 3Q18/9M18 win rates being lower at 2.9%/2.92% (vs. 3Q17/9M17: 3.1%/3.02%).
In the mass segment, GENS kept pace with the industry, clocking in 3Q18/9M18 market share of 38.8%/39.4% (vs. 39.0%/39.3% in 3Q17/9M17).
Outlook
GENS guides that it is still in a comfortable position to extend credit to attract VIP customers; although it remains highly cognisant of the near-term risks that the US/China trade war could pose on VIP flows. It deems its receivables position as very manageable.
GENS recognises that regional competition in the mass segment is stiff; hence, it aims to continually upgrade its facilities. For Japan, the bidding process is estimated to start in 2H19F.
Market Unduly Pricing in Watershed Valuations
At 5.8x FY19F EV/EBITDA, the market is pegging GENS to trough valuations of end-FY15 to FY16, in our view. During that period, adjusted EBITDA was below S$900m, trade receivable impairments were above S$230m-260m p.a., and receivables balance was above S$200m.
9M18 adj. EBITDA, trade receivable impairments and end- Sep 18 trade receivable balances are on relatively firmer footing.
Maintain ADD; Lower Target Price Just to be Cautious on Global Uncertainties
We trim our FY19-20F adj. EBITDA forecasts as we opt to be cautious on forward earnings growth, and lower our FY19F EV/EBITDA Target Price basis to 10x, its average 5-year mean (vs. 11.5x previously) in light of global volatility.
But with share price upside of 43.6%, we see the stock as a value buy and maintain our ADD call.
Catalysts are higher-than-expected earnings growth; risks are vice versa.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....